Segmed partners with Nucs AI to advance AI validation for Precision Oncology and theranostics. Uniting Real-World Imaging Data and Predictive AI to Power the Next Generation of Precision Oncology "We have spent years building the data foundation that precision oncology requires. The next step has always been finding partners who know how to use it. The next step has always been partnering with teams who can turn it into clinical impact. " - Jie Wu, PhD, Co-founder & Chief Data Officer, Segmed Palo Alto, CA - July 14, 2026 - Segmed, Inc., a leader in real-world medical imaging and multimodal data for research and AI development, today announced a strategic partnership with Nucs AI, a company developing AI-powered diagnostic and predictive imaging biomarkers for oncology and theranostics, to build the validation foundation for the next generation of AI in oncology. Precision medicine, at its core, is the ability to predict whether a given patient will benefit from a given therapy. In radioligand therapy, for example, the landmark VISION trial found that more than half of patients treated with lutetium-177 PSMA therapy did not achieve a PSA response. Determining the most accurate prediction requires learning from imaging, clinical context, and outcomes together, at the scale and diversity of real-world care. Models built on narrow or single-site data tend to learn the quirks of one setting rather than the biology of the disease, and they generalize poorly to the real world. By bringing together Segmed's diverse, multi-institutional data library with Nucs AI's predictive models, this partnership attacks the data bottleneck that has constrained the field. Through the partnership, Nucs AI will access Segmed's network of de-identified imaging and clinical data spanning multiple institutions, geographies, cancer types, modalities, and treatment settings. These resources will support platform expansion and the development of next-generation predictive biomarkers and clinical intelligence solutions. The companies will also jointly develop disease-specific registries, curated research cohorts, real-world evidence initiatives, and validation frameworks to generate clinically meaningful insights for providers, researchers, pharma, and patients. Extending Segmed's data infrastructure into theranostics. Segmed's library spans more than 2,800 healthcare partner sites and 150 million imaging studies, representing one of the largest and most diverse real-world oncology datasets available for AI development. The partnership extends Segmed's data infrastructure into molecular imaging, radiopharmaceuticals, and theranostics, opening new applications in biomarker discovery, treatment response prediction, patient stratification, and clinical research. To underscore its commitment, Segmed is also making a strategic investment in Nucs AI to support the co-development of registries, evidence frameworks, and validation capabilities built on Segmed's library. Having already leveraged more than 72,000 lesions in the development and training of its existing models, Nucs AI is now poised for rapid scale. With access to the broader and deeper real-world datasets provided by Segmed, the platform will continue expanding its capabilities across new cancer types, imaging modalities, and clinical applications. "Models are not the bottleneck in precision medicine; data is. Specifically, diverse, multi-institutional data that pairs imaging with real clinical context and outcomes. Train on that, and you unlock accuracy and patient-level specificity that imaging alone simply leaves on the table. Just as important, it frees us to go after the problems that matter clinically, not only the ones where a clean dataset happens to exist. Our partnership with Segmed gives us both the breadth and the depth to build precision medicine that actually reaches the patient." - Nijat Ahmadov, CEO, Nucs AI "We have spent years building the data foundation that precision oncology requires. The next step has always been finding partners who know how to use it. Nucs AI is asking precisely the right clinical questions, ones that demand the kind of diverse, multi-institutional, outcomes-linked data we have built. This partnership is what that infrastructure was designed for." - Jie Wu, PhD, Co-founder & Chief Data Officer, Segmed Together, the companies are building the validation infrastructure required for the next era of precision oncology, in which imaging, clinical data, and outcomes are continuously connected to ensure that every patient receives the therapy most likely to benefit them. To mark the announcement, Nucs AI and Segmed hosted a joint webinar on July 14 at 12:00 p.m. ET as part of Segmed's Bytes of Innovation series. Watch the full episode. About Segmed. Segmed, Inc. streamlines access to diverse, high-quality real-world data, including medical imaging and clinical records, for biopharmaceutical R&D, AI development, and medical device innovation. With a global network of healthcare partners across five continents, Segmed provides researchers with approximately 150 million de-identified, standardized imaging datasets through its proprietary platform, empowering safer, faster, and more equitable healthcare advancements. For more information, visit www.segmed.ai or follow Segmed, Inc. on LinkedIn @segmed-ai. About Nucs AI. Nucs AI develops AI-powered diagnostic and predictive imaging biomarkers for oncology and theranostics. The company's platform combines medical imaging, clinical information, and advanced machine learning to support patient-specific treatment decisions, response prediction, and tumor quantification. For more information, visit www.nucs.ai.

Segmed, Verily band together to expand access to real-world imaging data. Pairing aims to to support patient-centered, data-driven healthcare innovation. April 30, 2026 Managing Editor Segmed Inc. is partnering with Verily to increase access to de-identified imaging datasets. Through the collaboration, Segmed is making its de-identified, diagnostic-grade imaging and associated clinical data more available by enabling researchers to explore curated datasets within Verily's precision health platform, Pre Exchange and Workbench environment, secure platforms designed to accelerate precision health research and discovery. The partnership reflects Segmed's commitment to supporting rigorous, privacy-first research while lowering barriers to entry for investigators across academia, life sciences, and healthcare artificial intelligence (AI), Segmed executives claim. "Advanced imaging data plays a critical role in precision medicine, particularly when combined with clinical and other biomedical data modalities," Segmed CEO David Gascoigne said. "By partnering with Verily, we're expanding responsible access to high-quality, de-identified imaging datasets, helping researchers generate insights faster to accelerate the development of diagnostics and therapies." Segmed's initial dataset available through Pre Exchange focuses on breast cancer and includes a longitudinal cohort of patients who underwent at least one digital breast tomosynthesis (DBT) exam and biopsy-proven malignant lesions. This dataset is drawn from Segmed's broader global imaging platform, which includes approximately 150 million de-identified imaging exams spanning modalities such as CT, MRI, X-ray, ultrasound, mammography, PET, SPECT, echocardiography, and DEXA. "This partnership with Segmed is an important step forward in advancing AI-powered precision health," Verily Chief Revenue Officer Bharat Rajagopal stated. "By integrating Segmed's curated real-world imaging and associated clinical data into Pre, we are empowering researchers with the comprehensive, multimodal data resources they need to unlock new insights and accelerate discovery." This partnership reflects Segmed's ongoing efforts to support patient-centered, data-driven healthcare innovation by enabling secure, scalable access to real-world imaging data and associated clinical data within trusted research environments. Segmed Inc. streamlines access to diverse, high-quality real-world data, including medical imaging and clinical records, for biopharmaceutical R&D, AI development, and medical device innovation. With a global network of healthcare partners across five continents, Segmed provides researchers with approximately 150 million de-identified, standardized imaging datasets through its proprietary platform, empowering safer, faster, and more equitable healthcare advancements. Verily is a data platform and technology company purpose-built to power AI for precision health. Verily offers AI-enabled solutions that transform multimodal health data into insights and actions that accelerate research and improve care for individuals and communities. Verily is positioned at the intersection of technology, data science, and healthcare to create tools that accelerate evidence generation, enable more personalized care, and help manage disease at a population level.

iMerit, Segmed and Advocate Health have released the largest open-source annotated breast tomosynthesis dataset to accelerate AI research in breast cancer detection. The dataset includes imaging studies from 558 female patients, with a balanced distribution of 271 malignant and 287 benign cases, all biopsy confirmed and interpreted by US Board Certified radiologists. The dataset focuses on early detection, with an average tumour size of 1.34cm and approximately 85% of lesions smaller than 2cm. Images use digital breast tomosynthesis and are provided in DICOM format with JSON annotations, fully de-identified under HIPAA and GDPR standards. The release aims to support development of AI tools for radiologists, addressing a critical need as an estimated 321,910 US women will be diagnosed with invasive breast cancer in 2026.